Goldman Sachs Group Inc. Decreases Stake in Shattuck Labs, Inc. $STTK

Key Points

• Goldman Sachs Group Inc. has reduced its stake in Shattuck Labs by 57.5%, now holding approximately 0.21% of the company with 102,313 shares valued at $97,000.
• AQR Capital Management increased its stake in Shattuck Labs by 265.4%, while other investors also made significant changes to their positions during the first quarter.
• The stock of Shattuck Labs is currently trading around $2.39, with an average target price of $4.00 according to analysts, who have given it a "Moderate Buy" rating.

Goldman Sachs Group Inc. trimmed its position in shares of Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) by 57.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 102,313 shares of the company's stock after selling 138,549 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.21% of Shattuck Labs worth $97,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock valued at $41,000 after purchasing an additional 31,355 shares during the last quarter. Nuveen LLC acquired a new position in Shattuck Labs in the first quarter valued at $50,000. Jacobs Levy Equity Management Inc. acquired a new position in Shattuck Labs in the first quarter valued at $81,000. ADAR1 Capital Management LLC acquired a new position in Shattuck Labs in the first quarter valued at $97,000. Finally, Deutsche Bank AG increased its stake in Shattuck Labs by 476.4% in the fourth quarter. Deutsche Bank AG now owns 116,868 shares of the company's stock valued at $141,000 after purchasing an additional 96,594 shares during the last quarter. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Stock Performance

Shares of STTK opened at $2.39 on Wednesday. The company has a market capitalization of $114.48 million, a P/E ratio of -1.98 and a beta of 1.64. Shattuck Labs, Inc. has a one year low of $0.69 and a one year high of $2.48. The stock has a 50-day moving average price of $1.35 and a 200 day moving average price of $1.09.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. As a group, equities research analysts forecast that Shattuck Labs, Inc. will post -1.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on STTK. Wall Street Zen upgraded Shattuck Labs from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Wedbush began coverage on Shattuck Labs in a research note on Monday, September 8th. They issued an "outperform" rating and a $4.00 target price for the company. Leerink Partners dropped their target price on Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating for the company in a research note on Thursday, August 14th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $4.00.

Insider Buying and Selling

In other news, Director Mona Ashiya bought 6,306,127 shares of Shattuck Labs stock in a transaction on Monday, August 25th. The shares were bought at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the acquisition, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This represents a -600.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc bought 6,306,127 shares of Shattuck Labs stock in a transaction on Monday, August 25th. The shares were purchased at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the acquisition, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.00% of the company's stock.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.